Search Results

United Therapeutics Corporation today announced that it has closed the merger of SteadyMed Ltd. with a subsidiary of United Therapeutics.

United Therapeutics Corporation and SteadyMed Ltd. announced today the signing of a definitive merger agreement under which United Therapeutics will acquire SteadyMed for $4.46 per share in cash at closing and an additional $2.63 per share in cash upon the achievement of a milestone related to the commercialization of Trevyent®.

Correvio Pharma Corp. today highlighted that United Therapeutics (NASDAQ: UTHR) has completed its acquisition of SteadyMed Ltd., Correvio’s partner and the licensor of Trevyent®.

The termination of the waiting period under the HSR Act satisfies one of the conditions to closing of the acquisition, which remains subject to other closing conditions, including the approval of the acquisition by SteadyMed’s shareholders.

Shares of SteadyMed Ltd. have skyrocketed more than 77 percent in premarket trading today after United Therapeutics announced it will acquire the company for a total of $216 million, including $75 million in contingent consideration.

Cardiome plans to submit regulatory filings for Trevyent in Europe and Canada shortly following SteadyMed’s NDA resubmission to the FDA.

The Board of Directors of Regel Therapeutics announced that Stephen J. Farr , PhD, begins today as Chief Executive Officer (CEO).

No clinical trials are required for the NDA resubmission.

Trevyent® is for the treatment of pulmonary arterial hypertension